Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neoantigen Reactive T Cells (First Affiliated Hospital of Wenzhou Medical University)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Wenzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Neoantigen Reactive T Cells (NRTs) developed by the First Affiliated Hospital of Wenzhou Medical University is a personalized cell-based immunotherapy for the treatment of advanced gastric cancer. The therapy involves the isolation of a patient's own T lymphocytes, which are then expanded and selected ex vivo for their specific ability to recognize and react against tumor-specific neoantigens—unique antigens resulting from non-synonymous mutations within the individual's tumor. Once re-infused into the patient, these NRTs are intended to mediate targeted immunologic cytotoxicity against gastric cancer cells. In clinical settings, this therapy is typically evaluated in combination with lymphodepleting chemotherapy and interleukin-2 (IL-2) to enhance T cell persistence and activity.
- Other names
- Neoantigen Reactive T CellsNeoantigen-reactive T cells
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Neoantigen Reactive T Cells (First Affiliated Hospital of Wenzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neoantigen Reactive T Cells (First Affiliated Hospital of Wenzhou Medical University).